Interconnectivity between cardiovascular and renal risks in diabetes to be presented by AstraZeneca at EASD meeting.

AstraZeneca will present at EASD -New data to highlight the potential of Farxiga in T2D and interconnectivity between CV and renal diseases Highlights include several abstracts evaluating the effects of Farxiga alone and in combination in treating T2D, and in patients with CV (including heart failure) and renal risk factors. Research into CaReMe diseases includes a recent trial on CV outcomes and mortality in people with T2D and associated comorbidities (Poster #1177). The results will illustrate the importance of identifying novel protection strategies for various T2D-related comorbidities, including heart failure and chronic kidney disease, and may have implications for investigating risk in T2D patients.

A further presentation will include 52-week results of Farxiga as an add-on therapy to Onglyza (saxagliptin) in addition to metformin, compared with insulin in patients with or without sulfonylurea therapy. For patients with T1D, insulin is the standard therapy with no oral treatment options approved to date. The latest sub-analysis (Poster #612) of pooled data from the DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type-1 Diabetes) clinical trial programme (DEPICT-1 and DEPICT-2) features an evaluation on the effect of Farxiga in T1D patients taking adjustable insulin treatment. The analysis will look at two composite endpoints, including those determining instances of weight gain, severe hypoglycaemia and diabetic ketoacidosis (DKA). Farxiga is currently not approved in T1D. AstraZeneca will also present an analysis from the CVD-REAL study (Poster #635) which evaluated the efficacy and safety of SGLT2 inhibitors vs. other glucose-lowering medicines. This additional analysis will look at data across a larger number of countries and patients, with a longer duration of follow up than previously evaluated.